AACR 2019: HDAC inhibition may combat resistance to anti-PD-1 therapy in patients with melanoma
A combination of the experimental histone deacetylase (HDAC) inhibitor entinostat with the anti-PD-1 therapeutic pembrolizumab…
A combination of the experimental histone deacetylase (HDAC) inhibitor entinostat with the anti-PD-1 therapeutic pembrolizumab…